|Bid||206.23 x 1100|
|Ask||206.60 x 2200|
|Day's Range||203.01 - 217.00|
|52 Week Range||16.41 - 331.68|
|Beta (5Y Monthly)||1.47|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||300.75|
Dr. Kathleen Jordan, SVP of Medical Affairs at Tia, joins Yahoo Finance’s Kristin Myers and Alexis Christoforous to discuss the latest on the coronavirus.
In the updated daily Japanese candlestick chart of NVAX, below, we can see that prices reached our $172 price target back in late July. The On-Balance-Volume (OBV) line looks like it turned higher in early March telling us that buyers of NVAX are once again more aggressive. In the weekly Japanese candlestick chart of NVAX, below, we can see a very impressive rally since early 2020.
Novavax said in March its coronavirus vaccine was 96.4% effective in a Phase 3 test. It's also effective against variants. It's now seeking authorization. Is NVAX stock a buy?